Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Capital Expenditures (2016 - 2025)

Cytokinetics (CYTK) has disclosed Capital Expenditures for 16 consecutive years, with $24.3 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $24.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $24.8 million for FY2025, 535.1% up from the prior year.
  • Capital Expenditures for Q4 2025 was $24.3 million at Cytokinetics, up from $5.7 million in the prior quarter.
  • The five-year high for Capital Expenditures was $24.3 million in Q4 2025, with the low at -$19.1 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $2.6 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Capital Expenditures surged 1247.51% in 2021, then plummeted 256.45% in 2024.
  • Over 5 years, Capital Expenditures stood at -$19.1 million in 2021, then surged by 60.76% to -$7.5 million in 2022, then surged by 101.03% to $77000.0 in 2023, then surged by 411.69% to $394000.0 in 2024, then soared by 6078.93% to $24.3 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $24.3 million, $5.7 million, and $394000.0 for Q4 2025, Q1 2025, and Q3 2024 respectively.